ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i6.2827ppharm-2554Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСовременные возможности применения дупилумаба у детейModern Possibilities of Usage Dupilumab in Childrenhttps://orcid.org/0009-0008-6300-8989КосоваА. А.KosovaAnna A.

Косова Анна Александровна, студентка 

119435, Москва, ул. Большая Пироговская, д. 2, стр. 4

Anna А. Kosova, student 

2, Bolshaya Pirogovskaya Str., building 4, Moscow, 119435

olofb@list.ruhttps://orcid.org/0009-0009-5534-8243ФаянсА. В.FayansAnastasiya V.

Фаянс Анастасия Витальевна, студентка 

Москва

Anastasiya V. Fayans, student

Moscow

fanast@maii.ruhttps://orcid.org/0009-0006-0926-6579ИбадуллаеваA. Э.IbaduiiaevaAishan Е.

Ибадуллаева Айшан Эльбрус кызы, студентка 

Санкт-Петербург

Aishan Е. Ibaduiiaeva, student

Saint Petersburg

ayshan.ibadullayeva070700@mail.ruhttps://orcid.org/0009-0005-4807-9736ГусевК. С.GusevKirill S.

Гусев Кирилл Сергеевич, студент 

Москва

Kirill S. Gusev, student

Moscow

kguss01@mail.ruhttps://orcid.org/0009-0003-2090-5835НиколаеваА. Н.NikovaevaAnastaiya N.

Николаева Анастасия Николаевна, студентка 

Великий Новгород

Anastaiya N. Nikovaeva, student

Veliky Novgorod

 

n.nastja2002@iist.ruhttps://orcid.org/0009-0002-8330-0414БайбурдянД. Г.BayburdyanDayana G.

Байбурдян Даяна Гагиковна, студентка 

Санкт-Петербург

Dayana G. Bayburdyan, student

Saint Petersburg

supercatl42@gmaii.comhttps://orcid.org/0009-0005-7598-5515КалининД. В.KaiininDmitriy V.

Калинин Дмитрий Вячеславович, студент 

Москва

Dmitriy V. Kaiinin, student

Moscow

 

dimon080302@mail.ruhttps://orcid.org/0009-0006-9229-6962ИвановаЭ. Ю.IvanovaEieonora Yu.

Иванова Элеонора Юрьевна, студентка

Воронеж

Eieonora Yu. Ivanova, student

Voronezh

 

eleonora.ivanoval7@icloud.comhttps://orcid.org/0009-0000-1184-8734КорниловаМ. И.KorniiovaMarina I.

Корнилова Марина Игоревна, студентка 

Курск

Marina I. Korniiova, student

Kursk

m.kornilova.01@mail.ruhttps://orcid.org/0009-0007-2284-0608СеробянС. Г.SerobyanSaak G.

Серобян Саак Грачяевич, студент 

Москва

 

Saak G. Serobyan, student

Moscow

saak.king@mail.ruhttps://orcid.org/0009-0008-5532-4332ФоминаИ.. Р.FominaIrina R.

Фомина Ирина Романовна, студентка 

Санкт-Петербург

Irina R. Fomina, student

Saint Petersburg

irfomina@mail.ruhttps://orcid.org/0009-0006-1307-7690БухсаевЗ. Ш.BukhsaevZiki Sh.

Бухсаев Зики Шахларович, студент 

Курск

 

Ziki Sh. Bukhsaev, student

Kursk

 

zikibukhsaev@mail.ruПервый МГМУ им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian FederationРНИМУ им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationПСПбГМУ им. И.П. ПавловаРоссияPavlov First St. Petersburg State Medical UniversityRussian FederationНовГУРоссияNovgorod State UniversityRussian FederationРоссийский университет медициныРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationВГМУ им. Н.Н. БурденкоРоссияVoronezh State Medical University named after N.N. BurdenkoRussian FederationКГМУРоссияKursk State Medical UniversityRussian FederationСЗГМУ им. И.И. МечниковаРоссияNorth-Western State Medical University named after I.I. MechnikovRussian Federation202409012025216520533Copyright © Косова А.А., Фаянс А.В., Ибадуллаева A.Э., Гусев К.С., Николаева А.Н., Байбурдян Д.Г., Калинин Д.В., Иванова Э.Ю., Корнилова М.И., Серобян С.Г., Фомина И.Р., Бухсаев З.Ш., 20242024Косова А.А., Фаянс А.В., Ибадуллаева A.Э., Гусев К.С., Николаева А.Н., Байбурдян Д.Г., Калинин Д.В., Иванова Э.Ю., Корнилова М.И., Серобян С.Г., Фомина И.Р., Бухсаев З.Ш.Kosova A.A., Fayans A.V., Ibaduiiaeva A.Е., Gusev K.S., Nikovaeva A.N., Bayburdyan D.G., Kaiinin D.V., Ivanova E.Y., Korniiova M.I., Serobyan S.G., Fomina I.R., Bukhsaev Z.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2554

Дупилумаб — это генно-инженерный иммунобиологический препарат, который в последние годы все чаще используется для лечения бронхиальной астмы (БА), атопического дерматита (АтД) и эозинофильного эзофагита (ЭЭ) у детей. Цель исследования — проанализировать современные литературные данные, посвященные применению дупилумаба в лечении БА, АтД и ЭЭ у детей. Несмотря на недолгую историю применения дупилумаба в педиатрической популяции, его использование показало многообещающие результаты при лечении множества состояний, в патогенезе которых лежит Т2-воспаление, в первую очередь БА, АтД и ЭЭ. Он продемонстрировал эффективность у пациентов с различными клиническими проявлениями, характеризующимися умеренным и тяжелым течением или рефрактерностью к лечению, и привел к улучшению качества жизни пациентов. С расширением применения дупилумаба появляется все больше данных о его полезности в лечении других заболеваний, опосредованных Т-клетками.

Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.

дупилумаббронхиальная астмаатопический дерматитэозинофильный эзофагитдетиdupilumabbronchial asthmaatopic dermatitiseosinophilic esophagitischildrenReferencesКоннов П.Е., Арсеньева А.А. Эффективность и безопасность применения первого таргетного биологического препарата дупилумаб в терапии тяжелого непрерывно-рецидивиру-ющего атопического дерматита // Вестник дерматологии и венерологии. — 2023. — Т. 99. — № 1. — С. 62-70. — https://doi.org/10.25208/vdvl384Konnov РЕ, Arsenieva AA. Efficacy and safety of the first targeted bioiogicai drug dupiiumab in the treatment of severe continuousiy reiapsing atopic dermatitis. Vestnik Dermatologii i Venerologii. 2023;99(l):62-70. (In Russ), https://doi.org/10.25208/vdvl384]Чурюкина Э.В. Дупилумаб: аспекты применения при тяжелой бронхиальной астме в реальной клинической практике // Практическая пульмонология. — 2022. — № 2. — С. 3-10. — https://doi.org/10.24412/2409-6636-2022-12937Churyukina EV. Dupiiumab: aspects of use in severe bronchiai asthma in reai ciinicai practice. Prakticheskaya pulmonologiya. 2022;(2):3-10. (In Russ), https://doi.org/10.24412/2409-6636-2022-12937Глухова E.A., Кувшинова Е.Д., Ревякина B.A. Опыт применения дупилумаба у пациентов с тяжелым атопическим дерматитом//Аллергология и иммунология в педиатрии. — 2022. — № 3. — С. 14-23. — https://doi.org/10.53529/2500-1175-2022-3-14-23Giukhova EA, Kuvshinova ED, Revyakina VA. Experiencewith dupiiumab in patients with atopic dermatitis. Allergology and Immunology in Paediatrics. 2022;(3):14-23. (In Russ), https://doi.org/10.53529/2500-1175-2022-3-14-23Drugs@FDA: FDA-Approved Drugs, in: U.S. Food & Drug Administration. Available online: https://www.accessdata.fda.gov/scripts/cder/daf. Accessed on November 08, 2024.Drugs@FDA: FDA-Approved Drugs, in: U.S. Food & Drug Administration. Available online: https://www.accessdata.fda.gov/scripts/cder/daf. Accessed on November 08, 2024.Augustin M, Bauer A, Ertner K, et al. Dupiiumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatol Ther (Heidelb). 2023;13(3):803-816. https://doi.org/10.1007/sl3555-023-00894-3Augustin M, Bauer A, Ertner K, et al. Dupiiumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatol Ther (Heidelb). 2023;13(3):803-816. https://doi.org/10.1007/sl3555-023-00894-3SilverbergJI, BarbarotS, Gadkari A, etal. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. https://doi.org/10.1016/J.anai.2020.12.020SilverbergJI, BarbarotS, Gadkari A, etal. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. https://doi.org/10.1016/J.anai.2020.12.020Потекаев FI.Fl., Серов Д.НІ., Михайлова И.А. и др. Современные аспекты патогенеза и терапии атопического дерматита // Клиническая дерматология и венерология. — 2019. — Т. 18. — № 3. — С. 259-263. — https://doi.org/10.17116/klinderma201918031259Potekaev NN, Serov DN, Mikhailova IA, et al. Current aspects of pathogenesis and treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya I venerologlya. 2019;18(3):259-263. (In Russ), https://doi.org/10.17116/klinderma201918031259Paller AS, Weidinger S, Capozza K, et al. Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey). Dermatol Ther (Heidelb). 2023;13(4):961-980. https://doi.org/10.1007/sl3555-022-00850-7Paller AS, Weidinger S, Capozza K, et al. Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey). Dermatol Ther (Heidelb). 2023;13(4):961-980. https://doi.org/10.1007/sl3555-022-00850-7Flarb FI, Chatila TA. Mechanisms of Dupiiumab. Clin Exp Allergy. 2020;50(1):5-14. https://doi.org/10.llll/cea.13491Flarb FI, Chatila TA. Mechanisms of Dupiiumab. Clin Exp Allergy. 2020;50(1):5-14. https://doi.org/10.llll/cea.13491Flamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupiiumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J A/Zergy CTin Immunol. 2014;134(6):1293-1300. https://doi.org/10.1016/J.Jaci.2014.10.013Flamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupiiumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J A/Zergy CTin Immunol. 2014;134(6):1293-1300. https://doi.org/10.1016/J.Jaci.2014.10.013Wang A, Zhou Y, Luo Y, et al. Fligh loading-dose of dupiiumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https://doi.org/10.3389/fimmu.2023.1160710Wang A, Zhou Y, Luo Y, et al. Fligh loading-dose of dupiiumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https://doi.org/10.3389/fimmu.2023.1160710BlauveltA, Guttman-YasskyE, Paller AS, etal. Long-Term Efficacy and Safety of Dupiiumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365-383. https://doi.org/10.1007/s40257-022-00683-2BlauveltA, Guttman-YasskyE, Paller AS, etal. Long-Term Efficacy and Safety of Dupiiumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365-383. https://doi.org/10.1007/s40257-022-00683-2Ferrucci S, Casazza G, Zussino M, et al. Predictive Factors of Early Response to Dupiiumab in Patients with Moderate-to-Severe Atopic Dermatitis. J Clin Med. 2023;12(20):6575. https://doi.org/10.3390/Jcml2206575Ferrucci S, Casazza G, Zussino M, et al. Predictive Factors of Early Response to Dupiiumab in Patients with Moderate-to-Severe Atopic Dermatitis. J Clin Med. 2023;12(20):6575. https://doi.org/10.3390/Jcml2206575Kim EJ, Hlobik M, Ho T. Effectiveness of dupiiumab in pediatric patients with a nummular phenotype of atopic dermatitis. Pediatr Dermatol. 2024;41(3):455-457. https://doi.org/10.llll/pde.15541Kim EJ, Hlobik M, Ho T. Effectiveness of dupiiumab in pediatric patients with a nummular phenotype of atopic dermatitis. Pediatr Dermatol. 2024;41(3):455-457. https://doi.org/10.llll/pde.15541Kim JW, Kim M, Ahn GS, Na Jl. Dupilumabprovidesrapid improvement for morphologic variants of paediatric atopic dermatitis: A case series. Indian J Dermatol Venereol Leprol. 2022;88(6):834-839. https://doi.org/10.25259/IJDVL_759_2021Kim JW, Kim M, Ahn GS, Na Jl. Dupilumabprovidesrapid improvement for morphologic variants of paediatric atopic dermatitis: A case series. Indian J Dermatol Venereol Leprol. 2022;88(6):834-839. https://doi.org/10.25259/IJDVL_759_2021Gelato F, Mastorino L, Stepkina E, et al. Is Dupiiumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? J Clin Med. 2023;12(6):2189. https://doi.org/10.3390/Jcml2062189Gelato F, Mastorino L, Stepkina E, et al. Is Dupiiumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? J Clin Med. 2023;12(6):2189. https://doi.org/10.3390/Jcml2062189Мурашкин H.H., Опрятин Л.А., Павлова E.C. и др. Эффективность и безопасность дупилумаба при тяжелом атопическом дерматите у детей в возрасте до 6 лет: два клинических случая // Вопросы современной педиатрии. — 2023. — Т. 22. — № 5. — С. 443-449. — https://doi.org/10.15690/vsp.v22i5.2622Murashkin NN, Opryatin LA, Pavlova ES, et al. Dupiiumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases. Voprosy sovre-mennoi pediatrii — Current Pediatrics. 2023;22(5):443-449. (In Russ), https://doi.org/10.15690/vsp.v22i5.2622Kamphuis E, BoesJes CM, Loman L, et al. Dupiiumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol. 2022;33(12):el3887. https://doi.org/10.1111/pai.l3887Kamphuis E, BoesJes CM, Loman L, et al. Dupiiumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol. 2022;33(12):el3887. https://doi.org/10.1111/pai.l3887Paller AS, Simpson EL, Siegfried EC, et al. Dupiiumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919. https://doi.org/10.1016/S0140-6736(22)01539-2Paller AS, Simpson EL, Siegfried EC, et al. Dupiiumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919. https://doi.org/10.1016/S0140-6736(22)01539-2Paller AS, Siegfried EC, Thaęi D, et al. Efficacy and safety of dupiiumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293. https://doi.0rg/lO.lOl6/J.Jaad.2020.06.054Paller AS, Siegfried EC, Thaęi D, et al. Efficacy and safety of dupiiumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293. https://doi.0rg/lO.lOl6/J.Jaad.2020.06.054Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupiiumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(l):44-56. DOI: 10.1001/Jamaderma-tol.2019.3336Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupiiumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(l):44-56. DOI: 10.1001/Jamadermatol.2019.3336Siegfried EC, Simpson EL, Cork MJ, et al. Dupiiumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatol Ther (Heidelb). 2023;13(9):1987-2000. https://doi.org/10.1007/sl3555-023-00960-wSiegfried EC, Simpson EL, Cork MJ, et al. Dupiiumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatol Ther (Heidelb). 2023;13(9):1987-2000. https://doi.org/10.1007/sl3555-023-00960-wPaller AS, Bansal A, Simpson EL, et al. Clinically Meaningful Responsesto Dupiiumab In Adolescentswith Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119-131. https://doi.org/10.1007/s40257-019-00478-yPaller AS, Bansal A, Simpson EL, et al. Clinically Meaningful Responsesto Dupiiumab In Adolescentswith Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119-131. https://doi.org/10.1007/s40257-019-00478-yCork MJ, Lockshin B, Pinter A, et al. Clinically Meaningful Responses to Dupiiumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Derm Venereol. 2024;104:advl3467. https://doi.org/10.2340/actadv.vl04.13467Cork MJ, Lockshin B, Pinter A, et al. Clinically Meaningful Responses to Dupiiumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Derm Venereol. 2024;104:advl3467. https://doi.org/10.2340/actadv.vl04.13467Siegfried EC, Cork MJ, Katoh N, et al. Dupiiumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial. Am J Clin Dermatol. 2023;24(5):787-798. https://doi.org/10.1007/s40257-023-00791-7Siegfried EC, Cork MJ, Katoh N, et al. Dupiiumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial. Am J Clin Dermatol. 2023;24(5):787-798. https://doi.org/10.1007/s40257-023-00791-7Siegfried EC, Bieber T, Simpson EL, et al. Effect of Dupiiumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021;22(2):243-255. https://doi.org/10.1007/s40257-020-00583-3Siegfried EC, Bieber T, Simpson EL, et al. Effect of Dupiiumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021;22(2):243-255. https://doi.org/10.1007/s40257-020-00583-3Paller AS, Wollenberg A, Siegfried E, et al. Laboratory Safety of Dupiiumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs. 2021;23(5):515-527. https://doi.org/10.1007/s40272-021-00459-xPaller AS, Wollenberg A, Siegfried E, et al. Laboratory Safety of Dupiiumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs. 2021;23(5):515-527. https://doi.org/10.1007/s40272-021-00459-xPaller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. https://doi.org/10.1007/s40272-022-00553-8Paller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. https://doi.org/10.1007/s40272-022-00553-8Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. https://doi.org/10.1111/bjd.19460Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. https://doi.org/10.1111/bjd.19460Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. https://doi.org/10.1007/s40257-024-00859-yPaller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. https://doi.org/10.1007/s40257-024-00859-yGlobal Burden of Disease due to Asthma. In: The Global Asthma Report 2022. Available online: http://www.globalas-thmareport.org/burden/burden.php. Accessed on November 08, 2024.Global Burden of Disease due to Asthma. In: The Global Asthma Report 2022. Available online: http://www.globalas-thmareport. org/burden/burden.php. Accessed on November 08, 2024.Бяловский Ю.Ю., Глотов С.И., Ракитина И.С., Ермачкова А.Н. Патогенетические аспекты фенотипирования бронхиальной астмы // Российский медико-биологический вестник имени академика И.П. Павлова. — 2024. — Т. 32. — № 1. — С. 145–158. — https://doi.org/10.17816/PAVL0VJ181606Byalovskiy YuYu, Glotov SI, Rakitina IS, Ermachkova AN. Pathogenetic Aspects of Bronchial Asthma Phenotyping. I.P. Pavlov Russian Medical Biological Herald. 2024;32(1):145–158. (In Russ). https://doi.org/10.17816/PAVL0VJ181606Ricciardolo FLM, Bertolini F, Carriero V. The Role of Dupilumab in Severe Asthma. Biomedicines. 2021;9(9):1096. https://doi.org/10.3390/biomedicines9091096Ricciardolo FLM, Bertolini F, Carriero V. The Role of Dupilumab in Severe Asthma. Biomedicines. 2021;9(9):1096. https://doi.org/10.3390/biomedicines9091096Maison N, Omony J, Illi S, et al. T2-high asthma phenotypes across lifespan. Eur Respir J. 2022;60(3):2102288. https://doi.org/10.1183/13993003.02288-2021Maison N, Omony J, Illi S, et al. T2-high asthma phenotypes across lifespan. Eur Respir J. 2022;60(3):2102288. https://doi.org/10.1183/13993003.02288-2021Игнатова Г.Л., Антонов В.Н., Макарова Е.А., Кочеткова С.А. Опыт использования дупилумаба в лечении тяжелой бронхиальной астмы // Терапевтический архив. — 2020. — Т. 92. — № 8. — С. 95–99. — https://doi.org/10.26442/00403660.2020.08.000718Ignatova GL, Antonov VN, Makarova EA., Kochetkova SA. Experience of using dupilumab in the treatment of severe asthma. Therapeutic Archive. 2020;92(8):95–99. (In Russ). https://doi.org/10.26442/00403660.2020.08.000718Tajiri T, Suzuki M, Nishiyama H, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int. 2024;73(3):406–415. https://doi.org/10.1016/j.alit.2024.02.002Tajiri T, Suzuki M, Nishiyama H, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int. 2024;73(3):406–415. https://doi.org/10.1016/j.alit.2024.02.002Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. https://doi.org/10.3390/children9081253Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. https://doi.org/10.3390/children9081253Scott G, Asrat S, Allinne J, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091. https://doi.org/10.1016/j.cyto.2022.156091Scott G, Asrat S, Allinne J, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091. https://doi.org/10.1016/j.cyto.2022.156091Pelaia C, Pelaia G, Crimi C, et al. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel). 2022;10(6):974. https://doi.org/10.3390/vaccines10060974Pelaia C, Pelaia G, Crimi C, et al. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel). 2022;10(6):974. https://doi.org/10.3390/vaccines10060974Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/ NEJMoa1804092Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092Jackson DJ, Bacharier LB, Phipatanakul W, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023;131(1):44–51.e4. https://doi.org/10.1016/j.anai.2023.03.014Jackson DJ, Bacharier LB, Phipatanakul W, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023;131(1):44–51.e4. https://doi.org/10.1016/j.anai.2023.03.014Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-toSevere Asthma. J Allergy Clin Immunol Pract. 2023;11(4):1213– 1220.e2. https://doi.org/10.1016/j.jaip.2022.11.043Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-toSevere Asthma. J Allergy Clin Immunol Pract. 2023;11(4):1213– 1220.e2. https://doi.org/10.1016/j.jaip.2022.11.043Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению // Пульмонология. — 2022. — Т. 32. — № 3. —С. 393–447. — https://doi.org/10.18093/0869-01892022-32-3-393-447Chuchalin AG, Avdeev SN, Aisanov ZR, et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pul’monologiya. 2022;32(3):393–447. (In Russ). https://doi.org/10.18093/0869-0189-2022-32-3-393-447Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003Rajvanshi N, Kumar P, Goyal JP. Global Initiative for Asthma Guidelines 2024: An Update. Indian Pediatr. 2024;61(8):781–786.Rajvanshi N, Kumar P, Goyal JP. Global Initiative for Asthma Guidelines 2024: An Update. Indian Pediatr. 2024;61(8):781–786.Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021;385(24):2230–2240. https://doi.org/10.1056/NEJMoa2106567Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021;385(24):2230–2240. https://doi.org/10.1056/NEJMoa2106567Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S22132600(21)00322-2Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S22132600(21)00322-2Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. https://doi.org/10.1016/j.jaip.2019.08.050Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. https://doi.org/10.1016/j.jaip.2019.08.050Bourdin A, Papi AA, Corren J, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76(1):269–280. https://doi.org/10.1111/all.14611Bourdin A, Papi AA, Corren J, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76(1):269–280. https://doi.org/10.1111/all.14611Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils 500 cells·μL-1. Eur Respir J. 2022;59(6):2102577. https://doi.org/10.1183/13993003.02577-2021Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils 500 cells·μL-1. Eur Respir J. 2022;59(6):2102577. https://doi.org/10.1183/13993003.02577-2021Bleecker ER, Panettieri RA Jr, Lugogo NL, et al. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils. J Immunol Res. 2023;2023:9943584. https://doi.org/10.1155/2023/9943584Bleecker ER, Panettieri RA Jr, Lugogo NL, et al. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils. J Immunol Res. 2023;2023:9943584. https://doi.org/10.1155/2023/9943584Bacharier LB, Guilbert TW, Katelaris CH, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. J Allergy Clin Immunol Pract. 2024;12(4):948–959. https://doi.org/10.1016/j.jaip.2023.12.006Bacharier LB, Guilbert TW, Katelaris CH, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. J Allergy Clin Immunol Pract. 2024;12(4):948–959. https://doi.org/10.1016/j.jaip.2023.12.006Papadopoulos NG, Szefler SJ, Bacharier LB, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157– 2167. https://doi.org/10.1111/all.15743Papadopoulos NG, Szefler SJ, Bacharier LB, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157– 2167. https://doi.org/10.1111/all.15743Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;62(5):2300558. https://doi.org/10.1183/13993003.00558-2023Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;62(5):2300558. https://doi.org/10.1183/13993003.00558-2023Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36(6):1410-6. https://doi.org/10.1183/09031936.00117509Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36(6):1410-6. https://doi.org/10.1183/09031936.00117509Lu MA, Eckmann T, Ruvalcaba E, et al. Family management of asthma in Head Start preschool children. Ann Allergy Asthma Immunol. 2022;128(2):178–183. https://doi.org/10.1016/j.anai.2021.11.002Lu MA, Eckmann T, Ruvalcaba E, et al. Family management of asthma in Head Start preschool children. Ann Allergy Asthma Immunol. 2022;128(2):178–183. https://doi.org/10.1016/j. anai.2021.11.002Bacharier LB, Maspero JF, Katelaris CH, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024;12(1):45–54. https://doi.org/10.1016/S2213-2600(23)00303-XBacharier LB, Maspero JF, Katelaris CH, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024;12(1):45–54. https://doi.org/10.1016/S2213-2600(23)00303-XManti S, Giallongo A, Pecora G, et al. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study. Pediatr Pulmonol. 2023;58(4):1085–1091. https://doi.org/10.1002/ppul.26298Manti S, Giallongo A, Pecora G, et al. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study. Pediatr Pulmonol. 2023;58(4):1085–1091. https://doi.org/10.1002/ppul.26298Бурлуцкая А.В., Статова А.В., Долбнева О.В. и др. Эозинофильный эзофагит у детей: клинические случаи // Кубанский научный медицинский вестник. — 2022. — Т. 29. — № 4.— С. 94–106.— https://doi.org/10.25207/1608-6228-2022-29-4-94-106 [Burlutskaya AV, Statova AV, Dolbneva OV, et al. Eosinophilic Esophagitis in Children: Clinical Cases. Kuban Scientific Medical Bulletin. 2022;29(4):94–106. (In Russ). https://doi.org/10.25207/1608-6228-2022-29-4-94-106]Бурлуцкая А.В., Статова А.В., Долбнева О.В. и др. Эозинофильный эзофагит у детей: клинические случаи // Кубанский научный медицинский вестник. — 2022. — Т. 29. — № 4.— С. 94–106.— https://doi.org/10.25207/1608-6228-2022-29-4-94-106 [Burlutskaya AV, Statova AV, Dolbneva OV, et al. Eosinophilic Esophagitis in Children: Clinical Cases. Kuban Scientific Medical Bulletin. 2022;29(4):94–106. (In Russ). https://doi.org/10.25207/1608-6228-2022-29-4-94-106]Votto M, De Filippo M, Caimmi S, et al. A Practical Update on Pediatric Eosinophilic Esophagitis. Children (Basel). 2023;10(10):1620. https://doi.org/10.3390/children10101620Votto M, De Filippo M, Caimmi S, et al. A Practical Update on Pediatric Eosinophilic Esophagitis. Children (Basel). 2023;10(10):1620. https://doi.org/10.3390/children10101620Menard-Katcher C, Furuta GT, Kramer RE. Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes. J Pediatr Gastroenterol Nutr. 2017;64(5):701–706. https://doi.org/10.1097/MPG.0000000000001336Menard-Katcher C, Furuta GT, Kramer RE. Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes. J Pediatr Gastroenterol Nutr. 2017;64(5):701–706. https://doi.org/10.1097/MPG.0000000000001336Dowling PJ, Neuhaus H, Polk BI. The Role of the Environment in Eosinophilic Esophagitis. Clin Rev Allergy Immunol. 2019;57(3):330– 339. https://doi.org/10.1007/s12016-018-8697-9Dowling PJ, Neuhaus H, Polk BI. The Role of the Environment in Eosinophilic Esophagitis. Clin Rev Allergy Immunol. 2019;57(3):330– 339. https://doi.org/10.1007/s12016-018-8697-9Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(5):416–423. https://doi.org/10.1016/j.anai.2020.03.020Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(5):416–423. https://doi.org/10.1016/j.anai.2020.03.020Bawany F, Franco AI, Beck LA. Dupilumab: One therapy to treat multiple atopic diseases. JAAD Case Rep. 2020;6(11):1150–1152. https://doi.org/10.1016/j.jdcr.2020.08.036Bawany F, Franco AI, Beck LA. Dupilumab: One therapy to treat multiple atopic diseases. JAAD Case Rep. 2020;6(11):1150–1152. https://doi.org/10.1016/j.jdcr.2020.08.036Syverson EP, Rubinstein E. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. JPGN Rep. 2022;3(2):e180. https://doi.org/10.1097/PG9.0000000000000180Syverson EP, Rubinstein E. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. JPGN Rep. 2022;3(2):e180. https://doi.org/10.1097/PG9.0000000000000180Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589– 593. https://doi.org/10.1016/j.anai.2022.01.019Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589– 593. https://doi.org/10.1016/j.anai.2022.01.019Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990–1004. https://doi.org/10.1016/S2468-1253(23)00204-2Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990–1004. https://doi.org/10.1016/S2468-1253(23)00204-2Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. https://doi.org/10.1056/NEJMoa2205982Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. https://doi.org/10.1056/NEJMoa2205982Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. https://doi.org/10.1056/NEJMoa2312282Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. https://doi.org/10.1056/NEJMoa2312282McCann E, Chehade M, Spergel JM, et al. Validation of the novel Eosinophilic Esophagitis Impact Questionnaire. J Patient Rep Outcomes. 2023;7(1):120. https://doi.org/10.1186/s41687-023-00654-zMcCann E, Chehade M, Spergel JM, et al. Validation of the novel Eosinophilic Esophagitis Impact Questionnaire. J Patient Rep Outcomes. 2023;7(1):120. https://doi.org/10.1186/s41687-023-00654-zNguyen N, Burger C, Skirka S, et al. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023;77(4):536–539. https://doi.org/10.1097/MPG.0000000000003901Nguyen N, Burger C, Skirka S, et al. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023;77(4):536–539. https://doi.org/10.1097/MPG.0000000000003901Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab. ACG Case Rep J. 2022;9(11):e00887. https://doi.org/10.14309/crj.0000000000000887Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab. ACG Case Rep J. 2022;9(11):e00887. https://doi.org/10.14309/crj.0000000000000887Lee CJ, Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2024;22(2):252–258. https://doi.org/10.1016/j.cgh.2023.08.015Lee CJ, Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2024;22(2):252–258. https://doi.org/10.1016/j.cgh.2023.08.015

The authors declare that there are no conflicts of interest present.